Pechnick, R
Many treatment modalities have been developed to restore the immune tolerance and immmunoregulatory balance in autoimmune rheumatic diseases, including the use of peptide-based therapeutics or the use of nanoparticles-based nanotechnology

Disclosures: Binu John: Exact Sciences: Grant/Research Support, Genentech: Grant/Research Support, Glycotest, Inc: Grant/Research Support, Gilead: Grant/Research Support, Exelixis: Consultant, Takeda: Grant/Research Support, GlaxoSmithKline: Consultant, Astra Zeneca: Consultant, Dustin Bastaich: Nothing to Disclose, Catherine Mezzacappa: Nothing to Disclose, Raphaella Ferreira: Nothing to Disclose, Austen Hentschel: Nothing to Disclose, Andres Samos: Nothing to Disclose, Nadim Mahmud: Nothing to Disclose, Tamar Taddei: Nothing to Disclose, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Marina Serper: Transplant Genomics: Grant/Research Support, Grifols: Grant/Research Support, Eurofins: Grant/Research Support, Bassam Dahman: Nothing to Disclose 2073 HYDROPHOBIC SECONDARY BILE ACIDS INDUCE PRIMARY SCLEROSING CHOLANGITIS THROUGH THE LIVER-LARGE INTESTINE AXIS IN A CYP2C70 -/- / CYP2A12 -/- MOUSE WITH HUMAN-TYPE BILE ACID COMPOSITION -/- -/- Teruo Miyazaki 1 Hajime Ueda 1 Tadashi Ikegami 1 Akira Honda 1 , 1 Tokyo Medical University Ibaraki Medical Center Background: Primary sclerosing cholangitis (PSC) is characterized by fibrosis around the large bile duct (onion-skin lesions) and frequently complicates inflammatory bowel diseases (IBD)

In animal toxicology studies, no significant adverse effects have been observed even at doses far exceeding typical therapeutic ranges